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Abstract
Background: Breast cancer is the first cancer in women both in incidence and mortality. The treatment of breast
cancer benefited from the progress of chemotherapy and targeted therapies, but there was a parallel increase in
treatment costs. Despite a relatively high incidence of many sites of cancer, so far, there is no national register for
this disease in Morocco.
The main goal of this paper is to estimate the total cost of chemotherapy in the early stages of breast cancer due
to its frequency and the chances of patients being cured. This study provides health decision-makers with a first
estimate of costs and the opportunity to achieve the optimal use of available data to estimate the needs of anti-
mitotics and trastuzumab in Morocco.
Method: We start by evaluating the individual cost according to the therapeutic sub-groups, namely:
1. Patients needing chemotherapy with only anthracycline-based therapy.
2. Patients needing chemotherapy with both anthracycline and taxane but without trastuzumab.
3. Patients needing trastuzumab in addition to chemotherapy.
For each sub-group, the protocol of treatment is described, and the individual costs per unit, and for the whole
cycle, are evaluated.
Then we estimate the number of women suffering from breast cancer on the basis of two data bases available in
Morocco.
Finally, we calculate the total annual cost of treatment of breast cancer in Morocco.
Results: The total cost of breast cancer in Morocco is given in Moroccan dirhams (MAD), the US dollar at the current
exchange rate (MAD 10 = USD 1.30) and in international dollars or purchasing power parity (MAD 10 = PPP 1.95).
The cost of a therapy with trastuzumab is 8.4 times the cost of a sequential chemotherapy combining anthracy-
cline and taxane, and nearly 60 times the cost of chemotherapy based on anthracycline alone.
Globally, between USD 13.3 million and USD 28.6 million need to be devoted every year by the Moroccan health
authorities to treat women with localized breast cancer in keeping with international recommendations.
Discussion: According to our estimation methods, the complete cost of adjuvant chemotherapy including
trastuzumab will range from 1.3 to 2.4% of the global budget of the Moroccan Health Department (MAD 9.8 billion
or USD 1.274 billion). Unfortunately, only one-third of the Moroccan population has healthcare insurance whereas
for each patient the treatment with chemotherapy alone costs 1.15 times the annual minimum income (MAD
23,710 or USD 3,082), and treatment requiring both chemotherapy and trastuzumab costs 9.76 times the annual
minimum income. For the tumour over expressing HER2Neu, we need to treat 25 women in order to save (cure)
one woman: the calculated cost for one life saved is USD 663,000. The question is, is it cost-effective for an
emerging country?
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reproduction in any medium, provided the original work is properly cited.Conclusion: In this paper we aimed at evaluating the total cost of chemotherapy in the early stages of breast
cancer in order to provide health decision-makers with a first estimation and a good opportunity for the optimal
use of available data for the needs of antimitotics and trastuzumab in Morocco. Different protocols were
considered and the individual cost of the whole treatment was given according to therapies using anthracycline
alone, sequential chemotherapy combining anthracycline and taxane, and sequential chemotherapy with
trastuzumab. According to our estimations, Moroccan health authorities need to devote between USD 13.3 million
and USD 28.6 million every year in order to treat women suffering from localized breast cancer in ways consistent
with international recommended standards.
Background
Cancer is one of the leading causes of mortality world-
wide [1]. Morocco is an emerging country whose popu-
lation approached 30 million in 2004, with about 10% of
the people living in the region of Casablanca [2].
In Morocco, cancer is treated in five public centres
and six private structures in addition to the cancer
department of the military hospital. Despite a relatively
high incidence of many sites of cancer across the coun-
try, so far there is no national register for this disease.
In 2004, the first partial tentative provided a register of
cancers in the region of Casablanca. A total of 5,414
cases of cancer were registered in this region but only
3,336 were living in the region, of whom 1,833 were
women. In this region, of all sites of cancer, breast can-
cer was the most frequent representing 36.1%, followed
by lung cancer (25.5%) and cervical cancer (12.6%) [2].
Worldwide, breast cancer is the first cancer in women
both in incidence and mortality. It was also one of the
first localization to benefit from the recent progress in
systemic therapy especially targeted therapies [3]. Finan-
cing cancer treatment is a major challenge for both
developed and developing countries, but developing
countries are more vulnerable because of the limitations
in their pharmaceutical industries and because of
delayed diagnosis. Actually, several new drugs obtained
approval for use in oncology. The common characteris-
t i ci s ,h o w e v e r ,t h eh i g hc o s to ft h i sn e wg e n e r a t i o no f
treatment.
The main objective of the present study is to provide
an evaluation of the total cost of chemotherapy in the
early stages of breast cancer due to the frequency of this
cancer and the possibilities of cure. In the absence of
registries and accurate data, the estimates yielded by
this study will be of great importance to health deci-
sion-makers in Morocco, seeking to alleviate the disease
burden in general and the cost of breast cancer in
particular.
Methods
The first step was the estimation of the individual cost
according to the therapeutic sub-groups of breast cancer
in curative situation (defined by absence of distant
metastasis):
First of all, the different sub-groups of early breast
cancer were defined according to international consen-
s u sc r i t e r i aa si n d i c a t e db yt h eSaint Gallen and Saint
Paul de Vence panel of experts as follows [4]:
1. Patients who don’t need chemotherapy.
2. Patients needing chemotherapy
a. with only anthracycline-based therapy,
b. with both anthracycline and taxane but with-
out trastuzumab,
c. with trastuzumab.
Second, for each sub-group, the protocol of treatment
was described and for each protocol, we evaluated the
individual cost per unit and whole cycle-set using for
each drug the price of the cheapest generic as indicated
by the Agence Nationale de l’Assurance Maladie which
gives the average public price (APP) in Moroccan dir-
hams (MAD).
The second step was to evaluate the total number of
women suffering from breast cancer. In the absence of a
national register of cancer, two databases were used to
estimate the total number of women with breast cancer:
1) A first database was provided by the annual pub-
lic cancer centres treating patients with breast can-
cer. In this case, the total number of women
suffering from breast cancer is obtained by adding
the numbers of patients with localized breast cancer
diagnosed in 2007 at the four public cancer centres
in Morocco (Rabat, Casablanca, Agadir, and Oujda).
This method is based on hospital cancer registries.
2) A second database was given by the regional reg-
ister of cancer in Casablanca. In this case, the total
number of women suffering from breast cancer is
estimated by extrapolation, based on the assumption
that the rate of breast cancer in Morocco is equiva-
lent to the regional rate provided by the register of
Casablanca (this source is a population-based cancer
register, monitoring the frequency of cancer sub-
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reports from different sources of clinicians and
pathologists). It should be stressed that collected
data are checked automatically to eliminate potential
inaccuracies and duplicated cases.
The third step was to calculate the total cost of the
treatment of breast cancer in curative situation in Mor-
occo. In this stage, the percentages of patients assigned
to each protocol were calculated in order to compute
the total cost, with appropriate weights used for each
treatment.
Results
Estimation of the total cost of breast cancer treatment
in Morocco is based on the estimation of individual
treatment cost which, in turn, is based on the type of
protocol applied. Women who need adjuvant che-
motherapy may have one of three treatments: che-
motherapy based on anthracycline without taxane [3,4],
sequential chemotherapy combining anthracycline and
taxane without trastuzumab [3,5] or sequential che-
motherapy combining anthracycline, taxane and trastu-
zumab [5,6]. The details of each protocol are given in
Additional file 1.
1. The cost of individual treatment (at the exchange rate
MAD 10 = USD 1.3)
In order to evaluate the cost of individual treatment, we
need the following information: 1) the unit price of dif-
ferent drugs used in adjuvant treatment of breast cancer,
2) the kind of therapy according to the sub-groups and
the cost of a cycle for different protocols as indicated in
the annex. In the interests of clarity and simplicity, we
summarized this information in Table 1.
The total cost by cycle was calculated for each proto-
col (for median body area of 1.6 m
2)a n dg i v e ni nt h e
Moroccan currency and in US dollars. A protocol with
trastuzumab is about 20 times the cost of a protocol
with AC60. Similarly, for the individual whole treatment,
the cost of a therapy with trastuzumab is 8.4 times the
cost of a sequential chemotherapy combining anthracy-
cline and taxane, and nearly 60 times the cost of a che-
motherapy based on anthracycline alone.
2. Total recruitment of curative breast cancer in the
public cancer centre network
As indicated earlier, the first database used to estimate
the incidence of breast cancer and, consequently, its
cost, was based on the annual public cancer centres’
recruitment in breast cancer previously collected. In
2007, data were available from four centres as shown in
Table 2. The National Institute of Oncology and the
Centre in Casablanca are visited by patients from all
regions of Morocco whereas the recently created centres
in Agadir and Oujda remain regional.
3. Estimation of the incidence of curative breast cancer in
Morocco
We used a second database to estimate the incidence of
breast cancer in Morocco by extrapolating the rate of
breast cancer provided by the regional register of cancer
in Casablanca, to the whole country.
In 2004, the whole population of the Greater Casa-
blanca region was 3,615,903 including 1,833,648 women
and 1,782,255 men [2]. The global number of cancer
patients registered was 5,414 including 3,336 cases ori-
ginally from Casablanca [2]. Amongst 1,833 women
diagnosed with cancer, 36.1% were breast cancer cases
(662) [2]. Extrapolating these data to the whole country
yields an estimation of 5,500 cases of breast cancer
newly diagnosed in Morocco in 2004.
4. The percentages of patients assigned to each protocol
According to the statistics of the Moroccan cancer cen-
tres, about 75% of all newly diagnosed breast cancers
belong to the curable category, approximately 4,125
patients out of 5,500 [7]. The number of patients need-
ing chemotherapy represents 95% of all patients with
localized disease (3,900 out of 4,125) with the following
distribution [7]:
1) Patients who need anthracycline-based chemother-
apy: 1,950 (50%)
2) Patients who need chemotherapy with both anthra-
cycline and taxane: 1,950 (50%)
3) Patients who need trastuzumab in addition to
anthracycline and taxane: 780 (20%).
5. The total cost of breast cancer treatment in Morocco
Finally, we end up with two estimations of the total cost
of breast cancer treatment in Morocco. The first estima-
tion is based on the database provided by the cancer
centres’ statistics (Estimate1, 2007). The second estima-
tion was computed using the database given by the
regional register of cancer in Casablanca (Estimate2,
2004). Table 3 summarizes the costs expressed in Mor-
occan dirhams (MAD), American dollars (USD) and
international dollars (PPP).
6. Cost per life saved by the addition of trastuzumab
Adjuvant trials have shown that the addition of trastuzu-
mab to the chemotherapy improves the overall survival
by 4%. For 25 women treated, one is cured by this addi-
tion [6]. Consequently, the cost for one life saved is the
cost of treatment of 25 women treated by chemotherapy
plus one year of trastuzumab, namely, USD 663,000.
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Localized breast cancer is considered as curable whereas
the existence of metastasis means a palliative strategy
[3-5]. Usually, curative breast cancer is treated by a
combination of surgery, radiotherapy, chemotherapy and
hormone therapy (if positive hormone receptors) [3-5].
In this adjuvant setting, chemotherapy is indicated
based on prognostic factors which are specified by con-
sensus of scientific societies (ASCO, Saint Gallen, Saint
Paul de Vence....) [3-5]. The addition of trastuzumab to
chemotherapy depends on the over expression of the
human epidermal growth factor receptor (HER 2 Neu).
This receptor is targeted by the trastuzumab (monoclo-
nal antibody) [5]. Indeed, well designed clinical trials in
women with early breast cancer have demonstrated that
one year’s therapy with adjuvant intravenous trastuzu-
mab (a loading dose followed by 6 mg/kg every 3 weeks
or 2 mg/kg weekly) significantly improves disease-free
survival and overall survival compared to observation
(subsequent to chemotherapy) or chemotherapy alone in
women with HER 2 Neu-positive disease [5].
According to international recommendations, Moroc-
can health authorities need to devote between USD 13.3
million and USD 28.6 million every year in order to
treat women suffering from localized breast cancer. For
t h et u m o u ro v e re x p r e s s i n gH E R2N e u ,w en e e dt o
treat 25 women in order to save (cure) one woman: the
calculated cost for one life saved is USD 663,000. Is it
cost-effective for an emerging country? This is a main
question that we leave with health decision-makers.
It should be stressed that the first database includes
only data from the public health system and excludes
statistics of the five private centres which are not avail-
able. The cost is certainly higher than the USD 13.3 mil-
lion per year estimated by this method. Conversely, the
second method using the estimated incidence yielded a
cost of USD 28.6 million per year but it assumes that all
the new breast cancer cases are treated. Actually, only
approximately one-third of the cancer cases in Morocco
are treated.
According to our estimation methods, the complete
cost of adjuvant chemotherapy including trastuzumab
will represent between 1.3 and 2.4% of the global budget
of the Health Department (MAD 9.8 billion or USD
1.274 billion). Unfortunately, only one-third of the Mor-
occan population has healthcare insurance whereas for
each patient the treatment with chemotherapy alone
costs 1.15 times the annual minimum income (MAD
Table 1 Unit price for different drugs, cost of protocols by cycle and cost of individual whole treatment (values given
in Moroccan dirhams and US dollars)
Cost in MAD Cost in USD
Drug (presentation form) Unit price Unit price
Doxorubicin (50 mg) 257 33.41
Cyclophosphamide (1000 mg) 56 7.28
Docetaxel (80 mg) 4,384 569.92
Trastuzumab (150 mg) 6,000 780.00
Protocol Cost by cycle Cost by cycle
AC60 650 84.50
Docetaxel 8,500 1,105.00
Trastuzumab 12,000 1,560.00
Sub-group therapy Individual cost of whole treatment Individual cost of whole treatment
Chemotherapy based on
anthracycline without taxane
3,900 507.00
Sequential chemotherapy combining
anthracycline and taxane
27,450 3,568.50
Sequential Chemotherapy and
Trastuzumab (targeted therapy)
23,1450 30,088.50
The cost of a protocol with trastuzumab is nearly 20 times the cost of a protocol with AC60. For the individual whole treatment, the cost of a therapy with
trastuzumab is 8.4 times the cost of a chemotherapy with anthracycline and taxane, and nearly 60 times the cost of a chemotherapy based on anthracycline
alone.
Table 2 Curative breast cancer treated in different public
cancer centres in Morocco
National Institute of Oncology (NIO) 770
Centre of Casablanca 690
Regional Centre of Oujda 200
Regional Centre of Agadir 180
Global recruitment 1840
The two centres in Oujda and Agadir are regional centres recently created,
whereas the two centres in Rabat and Casablanca are older and attract
patients from all regions of Morocco.
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motherapy and trastuzumab costs 9.76 times the annual
minimum income.
Comparison of the price of trastuzumab in different
countries as reported in Table 4 shows that costs in
Morocco are less than western countries but it is still
expensive compared to income [8-10].
Limitation of our study:
Some data used to calculate the number of patients
candidate to chemotherapy like the ratio localized/meta-
static and ratio of involvement of auxiliary lymph nodes
are provided by local cancer centres’ registers but are
not published.
Using the second database to estimate the national
incidence of breast cancer by extrapolating the data
from the region of Casablanca to the whole country
assumes that this regional incidence is the average inci-
dence for the whole country. Such an assumption is
valid under two conditions:
1. Either breast cancer incidence is nearly uniform
through all regions, or
2. There is a compensating effect between regions
with higher incidence and those with lower inci-
dence than that of Casablanca.
A third method could be considered: using a weighted
average of curative breast cancer treated in different
centres taking into account the ratio incidence/regional
population; but this method would have been biased
since the National Institute of Oncology in Rabat and
the Centre of Cancer in Casablanca attract patients
from across the country.
Conclusion
The burden of breast cancer is a major problem for
both developed and developing countries; but citizens of
developing countries are more vulnerable because of
delayed diagnosis and lack of funds that allow for appro-
priate treatment, especially for women with very limited
income. According to the figures released by the Inter-
national Agency for Research on Cancer [11], breast
cancer is the most frequent among all kinds of cancer
in Morocco either by incidence (36.5%) or by mortality
(19.7%). In the absence of national registries and accu-
rate data, however, the country remains unable to adopt
an optimal strategy that reduces as far as possible the
burden of breast cancer under the constraints of limited
resources.
In this paper we aimed to evaluate the global cost of
chemotherapy in the early stages of breast cancer in
order to provide health decision-makers with a first esti-
mation and the opportunity to make the best use of
available data for estimating the needs of antimitotics
and trastuzumab in the country. Despite the limitations
of our study as mentioned in the discussion section, we
have estimated the cost of a cycle for different protocols.
For the individual whole treatment, we found that the
cost of a therapy with trastuzumab is 8.4 times the cost
of a sequential chemotherapy combining anthracycline
and taxane, and nearly 60 times the cost of a che-
motherapy based on anthracycline alone. Nationwide,
Moroccan health authorities need to devote between
USD 13.3 million and USD 28.6 million every year in
order to treat women suffering from localized breast
cancer in ways that are consistent with international
recommendations.
Table 3 The total cost of breast cancer chemotherapy according to the cancer centres’statistics (2007) (Estimate1) and
according to the estimated incidence of breast cancer in Morocco (2004) (Estimate2)
Cost in MAD (×1000) Cost in USD (×1000) Cost in PPP (×1000)
Estimate1 Estimate2 Estimate1 Estimate2 Estimate1 Estimate2
Global cost of anthracycline- based therapy 3,432 7,605 446 989 669 1,483
Global cost of anthracycline and taxane based therapy 24,140 53,500 3,138 6,955 4,707 10,432
cost of trastuzumab 75,200 159,000 9,776 20,670 14,664 31,005
Totals 102,772 220,105 13,360 28,614 20,040 42,920
Between USD 13.3 and USD 28.6 millions need to be devoted every year by Moroccan health authorities to treat women with localized breast cancer according
to international recommendations.
Table 4 Comparison of the price of trastuzumab in different countries
Country Individual cost of trastuzumab in US dollars Individual cost of trastuzumab. Equivalent in local currency
Morocco USD 26,280 MAD 204,000
France USD 39,629 EUR 27,594
United Kingdom USD 41,247 GBP 25,866
USA USD 70,000 USD 70,000
Australia USD 44,146 AUD 50,000
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Additional file 1: Details of each protocol. In this additional file, we
give details of the sub-groups therapies and the type of protocol
assigned to each sub-group of early breast cancer.
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